29.4 C
Vientiane
Monday, June 9, 2025
spot_img
Home Blog Page 662

Bioheng Therapeutics Announces FDA Clearance of IND Application for CD7 UCAR T Cell Therapy in T-ALL/LBL

BOSTON, March 5, 2025 /PRNewswire/ — Bioheng Therapeutics US LLC (“Bioheng”), a clinical-stage biotech company dedicated to developing innovative universal CAR-T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for CTD402, a CD7-targeted universal CAR-T (UCAR-T) cell therapy, for the treatment of pediatric and adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL). The study approved by the FDA is a single-arm, open-label Phase Ib/II trial with a simplified dose-finding design, designed to optimize dosing and accelerate clinical development. 

“We are delighted that CTD402 has received IND clearance from the U.S. FDA for a Phase Ib/II trial with a simplified dose-finding design, accelerating our clinical development timeline in the United States,” stated Jiangtao Ren, Ph.D., President & Chief Scientific Officer (CSO) of Bioheng. “IIT study results showed an impressive ORR, alongside a favorable safety profile. These results validate our ANSWER® platform’s ability to deliver both rapid therapeutic impact and reduced patient risk, positioning CTD402 as a potential best-in-class therapy for T-cell malignancies.” 

About CTD402
CTD402 is a universal CAR-T cell product targeting CD7 derived from healthy donors and intended for the treatment of T-ALL/LBL. It is genetically modified to avoid fratricide, graft-versus-host disease (GvHD), and host-versus-graft rejection (HvG) while enhancing anti-tumor activity. CTD402 can be prepared in a single batch for multiple people, achieving an “off-the-shelf” capability for patients in need of CAR-T cell therapy. 

About T-ALL/LBL
T-ALL/LBL are distinct clinical presentations of the same malignancy, originating from immature T-cell lineage lymphoid cells and classified based on the degree of bone marrow involvement. [1] While frontline therapy achieves high complete remission (CR) rates, the majority of patients ultimately experience relapse. Relapsed or refractory (R/R) disease is associated with poor outcomes, with a 5-year overall survival (OS) rate of less than 20%.[2] 

About Bioheng
Bioheng Therapeutics is a clinical-stage company focused on allogeneic “off-the-shelf ” universal CAR-T therapies. Founded in 2017, we aim to develop the world’s leading allogeneic cell therapy platforms and products to address some of the most challenging unmet needs. 

References:
[1] Swerdlow S H, Campo E, Pileri S A, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, The Journal of the American Society of Hematology, 2016, 127(20): 2375-2390.
[2] Marks D I, Rowntree C. Management of adults with T-cell lymphoblastic leukemia[J]. Blood, The Journal of the American Society of Hematology, 2017, 129(9): 1134-1142. 

 

GOODYEAR EDS TIRE WINS 2025 TIRE TECHNOLOGY INTERNATIONAL AWARDS

SHANGHAI, March 5, 2025 /PRNewswire/ — The Goodyear Tire & Rubber Company proudly announces that its ElectricDrive Sustainable-Material (EDS) tire has been honored with the Environmental Achievement of the Year – Tire Design award at the 2025 Tire Technology International (TTI) Awards for Innovation and Excellence. This prestigious award was presented at the Tire Technology Expo held at Deutsche Messe in Hannover, Germany.

“This year’s winners demonstrate unprecedented innovation and dedication to new tire technologies. In this year’s Environmental Achievement categories, the judges were particularly impressed by Goodyear’s EDS tire, which showcased a unique combination of sustainability and tire design,” said Matt Ross, editor-in-chief of TTI and chairman of the Tire Technology Awards for Innovation and Excellence.

Unveiled at the 7th China International Import Expo (CIIE), the EDS tire represents a major step in Goodyear’s pursuit of developing the industry’s first 100% sustainable-material tire by 2030. As China’s first ISCC mark retail tire with over 70% sustainable materials, the EDS tire is engineered for electric vehicles.

“We are thrilled to receive this award!” said Nathaniel Madarang, Goodyear Asia Pacific President, “Goodyear’s EDS tire provides EV drivers an excellent option of high-performing tires with ISCC-certified sustainable materials exceeding 70%. We are committed to introducing the industry’s first 100% sustainable-material tire by 2030. Goodyear’s Better Future framework is an important enabler to realizing our strategic vision to be #1 in tires and service in Luxury, SUV and EV across Asia Pacific. We are looking forward to shaping a Better Future by working closely with our business partners.”

The EDS tire is designed to meet the growing demand for sustainable and high-performing tires in the electric vehicle sector. Engineered for the unique demands of EVs, the EDS tire delivers superior wet braking, enhanced handling, lower rolling resistance, and reduced noise, ensuring a sustainable and high-performance driving experience.

Goodyear has integrated corporate responsibility into its company culture. This commitment is deeply rooted within Goodyear’s Corporate Responsibility framework, known as Goodyear Better Future. The framework’s pillars — Sustainable Sourcing, Responsible Operations, Advanced Mobility and Inspiring Culture continue to guide Goodyear’s global operations.

About The Goodyear Tire & Rubber Company

Goodyear is one of the world’s largest tire companies. It employs about 68,000 people and manufactures its products in 53 facilities in 20 countries around the world. Its two Innovation Centers in Akron, Ohio, and Colmar-Berg, Luxembourg, strive to develop state-of-the-art products and services that set the technology and performance standard for the industry. For more information about Goodyear and its products, go to www.goodyear.com/corporate.

TECNO Debuts AI Glasses Series at MWC 2025, Pioneering Industry-Leading 50MP Photography and Ushering in a New Era of AI and AR Innovation

BARCELONA, Spain, March 5, 2025 /PRNewswire/ — On March 4, 2025, Innovative AI-driven technology brand TECNO unveiled the TECNO AI Glasses Series at MWC Barcelona 2025, bringing its show theme of “Create the AI Future” to life. The series is TECNO’s debut AI glasses product and comprises two powerful models – TECNO AI Glasses and TECNO AI Glasses Pro – offering the highest pixel AI glasses photography system in the industry. MWC Barcelona 2025 attendees can get their first glimpse of the series in person at booth 6B11, Hall 6, Fira Gran Via.

TECNO AI Glasses Series Products
TECNO AI Glasses Series Products

While TECNO AI Glasses Pro offer a convenient and futuristic AR display, both products boast customized lens modules, a smartphone-main-camera-grade OV50D sensor, and the ISP and advanced imaging algorithms from TECNO’s flagship CAMON 40 Premier smartphone. This achieves the industry-leading ultra-clear AI glasses imaging system sets a new standard for on-the-go image capture, while the series also supports groundbreaking TECNO AI functions such as the Ella AI Assistant, marking the arrival of a new generation of intelligent eyewear with futuristic AI capabilities.

TECNO AI Glasses Series Products Lifestyle
TECNO AI Glasses Series Products Lifestyle

Next-level Imaging with Industry-leading 50MP Ultra-Clear Imaging

The TECNO AI Glasses Series brings smartphone-grade imaging to AI glasses with the industry’s most advanced AI glasses image capture. The series boasts the highest resolution camera of any AI glasses and is equipped with a customized lens module and a smartphone-main-camera-grade OV50D sensor, along with the same ISP and advanced imaging algorithms as TECNO’s new flagship imaging smartphone, CAMON 40 Premier 5G. These components combine to help users capture outstanding high-quality images full of vivid detail in various lighting conditions. What’s more, the exclusive ColorVisionary filters allow users to get explore vibrant colors in their shots, and the exclusive “SmartSnap” function intelligently recognizes scenes, assists in shooting, and automatically generates attractive captions for easily recording life’s special moments. The series also supports AI-driven content creation, allowing direct sharing to social media with unique AI-generated captions.

Intelligent Interactions Empowered by TECNO AI

The TECNO AI Glasses Series is equipped with TECNO AI and offers seamless interactions with the Ella AI Assistant on hand to meet users’ needs. From activity planning to food recommendations, Ella AI Assistant serves as a reliable companion for enhancing daily life. In addition, the integrated AI Info function efficiently compiles notifications and data from multiple apps, distilling vast amounts of information into concise reports, saving users valuable time without removing their phone from their pocket. Meanwhile, the advanced AI recognition capability identifies objects and locations, enriching users’ exploration with relevant insights. For example, when approaching a restaurant, users can simply capture an image through the glasses to receive AI-analyzed ratings and related data about the establishment. With real-time translation supporting over 100 languages, TECNO AI’s Ella empowers highly accurate translations even for less common languages, breaking down language barriers and facilitating effortless communication. Additional features like memos and schedule reminders are easily managed through a compatible Android app, which are pair to the mostly Andriod 8.0 and above system devices.

Innovative Lightweight Technology and Long-lasting Battery

The TECNO AI Glasses Series combines lightweight, durable resin lenses with advanced technology for a superior user experience. The TECNO AI Glasses feature an aviator design style, while the TECNO AI Glasses Pro come in a browline style. Both are perfect for daily wear and offer an elegant look. With a 250mAh battery, the series delivers efficient power management, providing over 11 hours of music playback and 8 hours of mixed use after just 30 minutes of charging. Equipped with a high-quality 180mm² speaker and advanced audio technology, the series delivers clear sound while safeguarding privacy with anti-sound leakage features. Users can also enjoy seamless connectivity with Wi-Fi 16 and Bluetooth 5.4, ensuring a smooth and immersive experience for all daily needs.

TECNO AI Glasses Pro - Teleprompter Scenario
TECNO AI Glasses Pro – Teleprompter Scenario

TECNO AI Glasses Pro: Futuristic WaveGuide Technology AR Display

Allowing users to experience the future of augmented reality today, the TECNO AI Glasses Pro feature an advanced WaveGuide technology AR display, exclusively co-developed with Meta-Bounds, and a MicroLED screen for crisp image clarity. With a 30° field of view and over 1500 nits brightness, the glasses ensure great visibility, even in bright conditions. Ideal for navigation, meeting translation and other real-time applications, the Pro model provides a comfortable and immersive AR experience, making everyday tasks easier and more intuitive and elevating every moment with innovative AR display technology.

The new TECNO AI Glasses Series delivers unparalleled and futuristic AI-powered experiences for forward-looking consumers. As TECNO’s debut AI glasses product, the series represents TECNO’s ongoing commitment to innovation, to deliver the best and most advanced technologies that improve lifestyles for users around the world.

About TECNO
TECNO is an innovative, AI-driven technology brand with a presence in over 70 markets across five continents. Committed to transforming the digital experience in global emerging markets, TECNO relentlessly pursues the perfect integration of contemporary aesthetic design with the latest technologies and artificial intelligence. Today, TECNO offers a comprehensive ecosystem of AI-powered products, including smartphones, smart wearables, laptops, tablets, smart gaming devices, the HiOS operating system, and smart home products. Guided by its brand essence of “Stop At Nothing,” TECNO continues to pioneer the adoption of cutting-edge technologies and AI-driven experiences for forward-looking individuals, inspiring them to never stop pursuing their best selves and brightest futures. For more information, please visit TECNO’s official site: www.tecno-mobile.com.

 

TECNO Unveils Industry’s Lightest OLED Laptop MEGABOOK S14 at MWC 2025 with TECNO AI and Snapdragon X Elite Compute Platform

BARCELONA, Spain, March 5, 2025 /PRNewswire/ — On March 4, 2025, Innovative AI-driven technology brand TECNO unveiled its new MEGABOOK S14 – the industry’s lightest 14-inch OLED laptop – at MWC Barcelona 2025. As the latest device in the flagship MEGABOOK S Series, the MEGABOOK S14 offers a new 14-inch size, a stunning 2.8K OLED display and Snapdragon® X Elite compute platform, while weighing just 899g (31.7oz), perfectly balancing portability and performance. Even with such a lightweight design, the MEGABOOK S14 is packed with powerful AI capabilities to supercharge users’ productivity and creativity.  

The MEGABOOK S14 is designed for business professionals, creative visionaries, and passionate gamers with versatile and powerful functions to meet users’ diverse needs. Equipped with innovative TECNO AI, it offers seamless functionality even without internet access and easy connectivity across the TECNO AI Ecosystem, including smartphones and MEGAPAD tablets, to effortlessly assist with tasks from creative writing to content generation and daily task management.  

World’s Lightest 14-inch Laptop TECNO MEGABOOK S14
World’s Lightest 14-inch Laptop TECNO MEGABOOK S14

Unrivaled Ultralight Design Meets Unparalleled Performance

Offering more than just a sleek and refined visual aesthetic, the MEGABOOK S14’s magnesium-alloy design is exceptionally slim and lightweight. At just 899g (31.7oz), it is a perfect companion for users’ who need to take powerful performance with them on the go. MEGABOOK S14 is equipped with the outstanding power of Snapdragon® X Elite compute platform, the flagship chipset for AI PCs from Qualcomm Technologies. It features powerful Qualcomm OryonTM CPU, integrated high-performance Qualcomm® HexgonTM NPU and supports LPDDR5X. Designed for competitive performance in Windows Copilot+ PCs, it excels in demanding multitasking with its responsive design. The 12-core Qualcomm Oryon CPU, built on a 4nm architecture, optimizes intensive workloads and offers dual-core boost for rapid responsiveness. Equipped with a leading Qualcomm® AI engine and integrated Hexagon NPU, it delivers transformative experiences for creative tasks, video conferencing, security, and productivity assistance. The MEGABOOK S14 Series is equipped with Windows 11 for a smooth and user-friendly experience.

AI at Your Fingertips: Empowering a New Era of TECNO AI Productivity

The MEGABOOK S14  features the World’s first self-developed edge-side large-scale AI Model to integrate the TECNO AI as a cutting-edge AI productivity at every aspect of users’ workflow. The laptop features the world’s first AI Gallery on a Windows system, seamlessly connecting with TECNO smartphones to organize photos, create smart albums and allow text and voice search for images and duplicate detection – all without internet connection. The laptop’s TECNO AI also features the Ella AI Assistant to streamline tasks, manage schedules and allow easier connections. Users can also insert any topics into AI PPT, it will localized complete the PowerPoint presentations base on TECNO AI Model sources within minutes. Let users’ creative juices flow with AI Drawing functions, and enjoy AI Meeting Assistant’s offline meeting transcription with speaker identification, multilingual support, key point extraction and summaries. In addition, personal GPT functions feature a local knowledge base with source tracing and text translation. The MEGABOOK S14 also features TECNO PC Manager to help users easily manage and optimize their PC, enjoy these versatile AI functions and experience seamless TECNO devices connectivity to simplify tasks and boost productivity.

TECNO MEGABOOK S14 with External Graphics Dock
TECNO MEGABOOK S14 with External Graphics Dock

Unleash Creativity and Enjoy More Immersive Experiences with an External Graphics Dock

The MEGABOOK S14 features an External Graphics Dock with powerful NVIDIA Graphic Card and allowed quick assembly to empower creative experiences, embolden personalized performance to provide immersive 3A gaming and creative production. The MEGABOOK S14 also offers Intel ARL-H Ultra Series CPU for matching with this external graphic dock, which is satisfying different users’ demand and delivering professional performance on the ultra-light laptop. What’s more, the MEGABOOK S14 is TECNO’s first OLED laptop, equipped with a stunning 2.8K high resolution display. As a result, MEGABOOK S14 transforms viewing with vivid colors, supremely deep blacks, and outstanding overall picture quality. The laptop also offers a 120Hz high refresh rate, supporting users as they discover limitless productivity and creativity.

A Secure, Reliable, MEGA Experience

TECNO’s first OLED laptop is enhanced by a 91% screen-to-body ratio, as well as TÜV Rheinland eye comfort certification, making the MEGABOOK S14 perfect for immersive gaming and creative work. It also delivers impact audio with DTS:X Ultra powered by dual 2W speakers, allowing users to customize sound to their preferences. Adding to the MEGA experience, the MEGABOOK S14 also provides secure fingerprint login, WiFi 6E, backlit keyboard, light sensor, and a 2M webcam with D-Mic. With all the features, the MEGABOOK S14 is supporting up to 16 hours of daily usage.

In the dawning AI era, TECNO AI is key to unlocking new levels of productivity and creativity for users in emerging markets across the globe. The MEGABOOK S14 is TECNO’s vision for the future of computing, with comprehensive AI functions and TECNO AI Ecosystem interconnectivity delivering exceptional value and unforgettable AI-powered experiences to users across the world.

About TECNO

TECNO is an innovative, AI-driven technology brand with a presence in over 70 markets across five continents. Committed to transforming the digital experience in global emerging markets, TECNO relentlessly pursues the perfect integration of contemporary aesthetic design with the latest technologies and artificial intelligence. Today, TECNO offers a comprehensive ecosystem of AI-powered products, including smartphones, smart wearables, laptops, tablets, smart gaming devices, the HiOS operating system, and smart home products. Guided by its brand essence of “Stop At Nothing,” TECNO continues to pioneer the adoption of cutting-edge technologies and AI-driven experiences for forward-looking individuals, inspiring them to never stop pursuing their best selves and brightest futures. For more information, please visit TECNO’s official site: www.tecno-mobile.com.

Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries.
Qualcomm, Qualcomm Oryon, Hexagon, and Snapdragon are trademarks or registered trademarks of Qualcomm Incorporated.

Telkomcel Holds TAIS 2025, Strengthens Commitment to Innovation and Digital Transformation

DILI, Timor-Leste, March 5, 2025 /PRNewswire/ — Telkomcel has reaffirmed its commitment to driving innovation and accelerating digital transformation in Timor-Leste through the organization of the Telkomcel Annual International Summit (TAIS) 2025. As the leading telecommunications provider in Timor-Leste, Telkomcel continues to deliver innovative digital solutions to support economic growth and technology-based national development.

Left to Right : Abdul Rahman Ansyori, Chief Technology Officer (CTO) of Telin; Adir Ginting, Head of Enterprise at Google Indonesia; Rala Xanana Gusmão, Prime Minister of Timor-Leste; and Tomy Yunus, CEO & Co- Founder of Cakap.
Left to Right : Abdul Rahman Ansyori, Chief Technology Officer (CTO) of Telin; Adir Ginting, Head of Enterprise at Google Indonesia; Rala Xanana Gusmão, Prime Minister of Timor-Leste; and Tomy Yunus, CEO & Co- Founder of Cakap.

TAIS 2025 serves as a strategic platform that brings together stakeholders from the technology, business, and government sectors to discuss and collaborate on accelerating digitalization in Timor-Leste. The event features various flagship initiatives and renowned speakers who will share in-depth insights on digital transformation trends and strategies aligned with the national development vision.

One of the highlights of TAIS 2025 is the Digital Startup Showcase, which showcases leading technology startups from Indonesia, such as Cakap, Good Doctor, Nodeflux, and Widya Robotics. Visitors to the booths will have the opportunity to explore innovative digital solutions and interact directly with the innovators behind these startups.

The event also features a lineup of keynote speakers, including His Excellency Kay Rala Xanana Gusmão, Prime Minister of Timor-Leste; Abdul Rahman Ansyori, Chief Technology Officer (CTO) of Telin; Adir Ginting, Head of Enterprise at Google Indonesia; and Tomy Yunus, CEO & Co- Founder of Cakap. They will share insights during a Business Talk session titled “Timor-Leste Digital Connectivity: Driving Innovation, Empowering Generation”, which discusses the role of digital connectivity in driving innovation and empowering future generations.

TAIS 2025 offers a series of exciting events, including:

  • The First Digital Startup Showcase in Timor-Leste – Exhibitions on Vision Artificial Intelligence (AI), Health Tech Platforms, Facial Recognition AI, and Telkomcel’s Household Internet Broadband Access Solution.
  • Business Talk – A panel discussion with industry leaders and technology experts titled “Timor-Leste Digital Connectivity: Driving Innovation, Empowering Generation”.
  • Telkomcel Awards – Recognition for customers and strategic partners who have contributed to the development of digitalization in Timor-Leste.
  • Jornalista Hakerek Award – Appreciation for journalists actively contributing to news coverage on technology and digitalization.
  • Symbolic Handover of the Uma Domin Program – The construction of a service house and Telkomcel’s ESG commitment to empower the community in Manleu, in collaboration with the Jesus Futar Fuan Domin congregation.

Benedictus Ardiyanto Priyo, CEO of Telkomcel, emphasized that TAIS 2025 is a tangible manifestation of Telkomcel’s commitment to driving innovation to empower the nation, in line with its tagline “Empowering Innovation, Empowering the Nation“.

We believe that innovation is the key to building a better digital future. Through TAIS 2025, Telkomcel aims to strengthen collaboration with various stakeholders to create an inclusive and sustainable digital ecosystem,” said Benedictus Ardiyanto Priyo.

Chief Technology Officer of Telin, Abdul Rahman Ansyori, also added, “As part of the Telkom Group, Telin is committed to continuously delivering reliable and innovative digital infrastructure solutions to support economic growth and enhance connectivity in Timor-Leste. TAIS 2025 serves as a strategic opportunity for us to share insights and foster collaboration in building a competitive digital ecosystem. We believe that strong connectivity will serve as the foundation for innovation and the empowerment of future generations.”

As part of its efforts to drive digital innovation, Telkomcel introduced Telkomcel DigiStar, the first local digital startup competition in Timor-Leste. This program aims to discover and empower local talents with significant potential to build a competitive digital ecosystem.

Behind Telkomcel DigiStar is Kay Olok Gusmão, a creative young individual appointed as the Youth Ambassador. In this role, Kay will inspire the youth of Timor-Leste to innovate in the digital world and bring positive impacts to the community.

The Uma Domin (Service House) built by Telkomcel is also a highlight of TAIS 2025. In collaboration with the Jesus Futar Fuan Domin congregation, Telkomcel provides a service and learning house for children in need in the Manleu area. Telkomcel employees will also offer lessons in digital skills, IT, marketing, and other relevant knowledge for the digital era.

Through TAIS 2025, Telkomcel is not only committed to delivering cutting-edge technological solutions but also to creating a digital ecosystem that empowers the community. This step aligns with Telkomcel’s mission to continue making tangible contributions to the community and national development in Timor-Leste.

About Telkomcel

Telkomcel is the leading telecommunications provider in Timor-Leste, playing a crucial role in driving the country’s digital transformation. With a reliable network and the latest digital solutions, Telkomcel not only meets personal communication needs but also enhances business productivity and supports the government sector.

As part of its commitment to accelerating digitalization and empowering society, Telkomcel has launched various programs and initiatives that support the development of a digital ecosystem in Timor-Leste. The company takes pride in its diverse workforce, with over 95% of its 200 employees being local talents, and 75% of managerial positions filled by the best sons and daughters of Timor-Leste. Additionally, Telkomcel supports gender equality, with 50% of its employees being women, demonstrating its commitment to inclusivity and leadership development. With a strong foundation in innovation, local empowerment, and gender equality, Telkomcel continues to be a key driver in shaping Timor-Leste’s digital future.

About Telin

Founded in 2007 as a company that provides a comprehensive suite of premium international carrier voice, data services, and business solutions tailored to meet the unique needs of wholesale, enterprise, digital player, and retail customers with operations. Telin operates in Indonesia, Singapore, Hong Kong SAR, Australia, Malaysia, Taiwan region, the United States, Timor Leste, the United Arab Emirates, and Myanmar, and also has representatives in the United Kingdom (UK), Philippines and India. Telin’s infrastructure spans 250,140 kilometres of cable system length, operates 58 Points of Presence, 10 global offices, and over 19 Tier II to Tier IV Data Centres in key locations, including Singapore, Hong Kong SAR, Timor Leste, and Indonesia.

For more information about Telin, visit www.telin.net

Business Plan Contest “Photonics Challenge 2025” was Successfully Held in Hamamatsu City, the Center of the Optical Industry

Three companies with outstanding optical technology – 
Beyond Optical Medical Technologies, Ectobrain Devices and Catana Corporation – presented
groundbreaking ideas and are awarded for their business plans

HAMAMATSU, Japan, March 5, 2025 /PRNewswire/ — The Central Japan Startup Ecosystem Consortium is pleased to announce that Photonics Challenge 2025, a business contest that supports the expansion of optical technology applications by startups and small and medium-sized enterprises (SMEs) nationwide that seek to create new value in society, was successfully held in Hamamatsu City.

Winners, finalists, and judges of Photonics Challenge 2025
Winners, finalists, and judges of Photonics Challenge 2025

The Central Japan Startup Ecosystem is comprised of Aichi prefecture, Nagoya City and Hamamatsu City in Shizuoka-prefecture and provides everything a startup needs – from highly trained workers in many specialized fields to opportunities to conduct feasibility studies with leading companies. There are also accelerator programs, financial support systems, innovative university seeds, and collaborative partnerships with ecosystems outside of Japan and also attract a wide range of entrepreneurs to this region.

Against this backdrop, Photonics Challenge is an annual competition sponsored by the Graduate University School for the Creation of New Photonics Industries. This year marked its sixth year and is the only business plan contest in Japan that specializes in optical technology. Seven finalists, selected from among applicants from all over Japan, presented their business plans at the final judging held on February 27 at Entetsu Hall in Hamamatsu City, after months of mentoring. Beyond Optical Medical Technologies, Ectobrain Devices and Catana Corporation successfully presented their groundbreaking ideas and were awarded for their respective business plans.

The awards were presented by the Chairman of the Judging Committee, Hiroyasu Ito, President of Graduate School for the Creation of New Photonics Industries.

For the 2025 Photonics Challenge, a new category was established for “Best Idea”, and applicable to individuals who have a passionate vision and business idea, including college or technical school students. Three individuals presented their ideas, and the winner will be provided opportunities to hone their entrepreneurship skills.

New Category for “Best Idea”. This was presented by Yoshihiro Asada, who was awarded this prize
New Category for “Best Idea”. This was presented by Yoshihiro Asada, who was awarded this prize

The 2025 Photonics Challenge winners are as follows:

1.  Best Business Award – prize of one million yen – Awarded to Beyond Optical Medical Technologies

2.  Best Challenge Award – prize of 800,000 yen – Awarded to Ectobrain Devices

3.  Shizuoka SME Excellence Award – prize of 300,000 yen – This award is for applicants whose base of operations is in Shizuoka Prefecture and was awarded to Catana Corporation

4.  Observer Award – prize of 300,000 yen – Awarded to HarvestX

5.  Best Idea Award – prize of 200,000 yen – Awarded to ASA-e

Profile of Award Winners

Best Business Award – Beyond Optical Medical Technologies

Beyond Optical Medical Technologies is developing a new surgical platform that uses near-infrared spectroscopic imaging to see deep inside the body during surgery. This allows surgeons to visualize tissues and structures that are normally invisible, reducing the risk of complications. Nariaki Okamoto of Beyond Optical Medical Technologies said, “Surgery today faces many complications, and fewer young people are pursuing it as a career. I believe collaboration between medicine and engineering is key to advancing surgical techniques, and I hope to create a future where surgeries are safer and more reassuring for everyone.”

Best Challenge Award – Ectobrain Devices

Ectobrain Devices is developing smart glasses to help Parkinson’s patients walk more easily and avoid falls. Parkinson’s patients often suffer from walking difficulties (gait disturbances) that are not effectively treated by existing medications. These glasses will automatically adjust to the patient’s needs, providing real-time assistance. Yu Nagashima of Ectobrain Devices said, “We are planning to launch as a startup from Hamamatsu University School of Medicine and will be registering the company next week, so I am very encouraged to receive this award.”

Shizuoka SME Excellence Award – Catana Corporation

Catana Corporation is pursuing international standardization (ISO/IEC) for their real-time lossless data compression technology, which is designed to reduce storage, bandwidth, and power consumption in industries like automotive, manufacturing, healthcare, and infrastructure. While already used in Japan, global adoption, particularly in the automotive sector with the goal of “installation in all commercially available vehicles,” requires meeting international standards demanded by overseas manufacturers. Nobuo Fujita, CEO & CTO of Catana Corporation said, “This is the first time we have participated in a business contest, so I’m very pleased to have won. I’m truly glad I participated because I received ideas and comments on the plan we presented.”

https://www.catana.co.jp/en/

Observer Award – HarvestX

HarvestX developed a system that uses multispectral cameras and AI to monitor strawberry growth, combined with a robot that automatically pollinates the plants. HarvestX plans to expand the technology to other crops. Yuki Ichikawa, Representative Director and CEO from HarvestX said, “I was actually just networking with other companies and had just entered the room when the award announcement was made. That just goes to show how passionate the other companies are, and this is a great opportunity to quickly find potential collaborators.”

https://harvestx.jp/en/ 

Best Idea Award – ASA-e

Yoshihiro Asada is a 1st year graduate student at Toyohashi University of Technology in Aichi Prefecture. Inspired by his grandfather who was diagnosed with diabetes, Yoshihiro is working to control soybeans without raising sugar levels so those suffering from the same condition can enjoy them. By controlling the components of soybeans using sensor data, ASA-e increases the sweetness of soybeans without raising blood sugar levels. Yoshihiro Asada said, “I will make further efforts to become a successful entrepreneur, and I would appreciate your continued support.”

Other Participating Finalists

(Business Category)

Deep Sensing

Deep Sensing is building robots that use AI to automatically scan underground structures without digging. These robots use radar to see inside, helping to identify missing persons during natural disasters or improve aging infrastructure.

SEtech

SEtech is developing a new type of sensor that reduces the burden on AI systems by processing information directly on the sensor itself. This “Anti-Imaging” approach reduces power consumption and data volume with a suite of sensors.

https://setech.co.jp/ 

Three-labs Inc.

Three-labs is a startup from Nagoya Institute of Technology using a new “Pulse Laser Grinding” (PLG) technology to re-sharpen cutting tools. Their laser-based method is more precise than traditional grinding wheels, allowing them to re-sharpen tools that couldn’t be re-sharpened before, saving manufacturer’s cost and reducing waste.

https://three-labs.com/

(Idea Category)

Mirai Iryo Innovators

Working towards a future without nerve damage during surgery through the use of Raman spectroscopy, which is based on the interaction of light with the chemical bonds of a substance.

Ryo Igarashi

Designing glasses for people who suffer from light sensitivity that act as sunglasses but without the dark lenses.  

Other event highlights

During the final deliberations, six of the past Photonics Challenge finalists each presented their business, introduced their current situation, and how far they have come since winning. These companies included: 

WIZRAY
https://wizray.jp/

Photon-Labo
http://photon-labo.jp/

Archilys
https://www.archilys.com/ArchilysCorp/ArchilysCorporation.html

Astech
https://www.astechk.co.jp/

Miibio
https://www.mii-bio.com/

Pi Photonics
https://www.piphotonics.com/en/

About the Central Japan Startup Ecosystem

In July 2020, Aichi prefecture, Nagoya City and Hamamatsu City in Shizuoka-prefecture became one of the four regional Startup Ecosystem Global Base Cities groups designated nationwide by the Japanese Cabinet Office. 

There are 848 startups in Central Japan, of which 209 are university-launched. An estimated 100.8 billion yen (from 2020 to 2024) of funds have been raised, in addition to accelerator programs, financial support systems, and innovative university seeds. 

Collaborative partnerships with Station F, INSEAD, BLOCK71, Paris &Co, Bpifrance, Venture Café, Plug and Play, Israel Innovation Authority, Tsinghua University, China Medical University, National University of Singapore, the University of Texas at Austin, Stanford University, North Carolina State University, University of Nebraska and the Indian Institute of Technology Hyderabad attract a diverse range of entrepreneurs to the region. 

For more information, please visit https://central-startup.jp/en/

Veeva CRM Pulse Improves Segmentation and Targeting with Brick-Level HCP Access Data for 21 Countries

Delivered quarterly, CRM Pulse is generated from more than 500 million Veeva CRM interactions for the industry’s most complete, timely, and accurate HCP access data

SINGAPORE, March 5, 2025 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced Veeva CRM Pulse, a data subscription that provides quarterly healthcare professional (HCP) access and multichannel engagement metrics for the life sciences industry. With HCP access data as an input for segmentation, targeting, and engagement planning, Pulse provides immediate value for commercial operations and data analytics teams.

Pulse is unique in giving customers HCP data that has:

  • True Industry Census: Based on global usage of Veeva’s leading CRM Suite, Pulse is the most complete, timely, and accurate data set for HCP access.
  • Unmatched Coverage: Access and engagement metrics by channel are available for more than three million HCPs across 102 specialties and 21 countries.
  • Aggregated for Data Privacy: HCP metrics are segmented and aggregated by country, specialty, and brick for data privacy.

“Pulse is a breakthrough data product that will greatly improve segmentation and targeting around the globe,” said Peter Stark, executive vice president of Veeva Data Cloud. “We look forward to working with our early customers to bring the value of CRM Pulse data to their commercial operations.”

Pulse is available for license to Veeva’s CRM customers today with 2024 quarterly data covering the United States, Canada, Germany, United Kingdom, France, Italy, Spain, Portugal, Austria, Switzerland, Netherlands, Belgium, Ireland, Hungary, Brazil, Mexico, Australia, New Zealand, South Korea, Taiwan, and Singapore. Quarterly data releases for 2025 will begin this April. Additional countries in Asia and Europe are planned for availability next year.

Veeva CRM Pulse is part of Veeva Data Cloud, which includes Veeva OpenData, Veeva Link, and Veeva Compass. For more information, visit veeva.com/Pulse.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.

 

CordenPharma Expands Peptide Platform with more than 500 Million Euro Greenfield Facility Construction in the Basel Region of Switzerland

  • CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and large peptide manufacturing facilities across Europe and the US.
  • In Switzerland, CordenPharma will invest >€500m to construct a greenfield site for small to large-scale peptide development and manufacturing located within the Basel region in Muttenz.
  • In its Colorado, US site, ongoing expansion will target additional large-scale peptide manufacturing capacity of existing lines as well as a greenfield construction for new production areas.

BASEL, Switzerland, March 5, 2025 /PRNewswire/ — Following its 16 July 2024 announcement, CordenPharma is pleased to share significant progress on its growth initiatives with a >€1 billion strategic investment in peptide development and manufacturing. The company’s ambitious expansion plans are set to propel its Peptide Platform business beyond the €1 billion sales milestone by 2028, reinforcing CordenPharma’s position as a market leader in integrated supply of small to large-scale services from APIs to Drug Products, for both Injectable and Oral Peptides.

[Photo by CordenPharma] An aerial sketch of CordenPharma’s future peptide manufacturing facility located at Getec Park in Muttenz, Switzerland.
[Photo by CordenPharma] An aerial sketch of CordenPharma’s future peptide manufacturing facility located at Getec Park in Muttenz, Switzerland.

As part of this strategy, CordenPharma has finalized plans to establish a state-of-the-art peptide manufacturing facility in Switzerland located at Getec Park in Muttenz, just 8 km outside Basel – a major biotech and pharma hub within Europe.

The decision to locate the plant near Basel is supported by several key advantages, including:

  • Efficient infrastructure, with existing systems for handling materials and processes that are crucial for state-of-the-art peptide manufacturing.
  • Optimal logistics, with streamlined access to transportation networks.
  • Established large-scale utilities already in place to support chemical manufacturing needs.
  • Talent pool access due to close proximity to Basel, a renowned pharma and biotech hub at the crossroads of Germany, France, and Switzerland, ensuring access to highly skilled professionals.
  • The surrounding industrial park ensures sustainable operational efficiency in a well-established manufacturing ecosystem with closed-loop energy and material cycles, as well as innovative waste-to-value streams, with a clear strategic path to net-zero.

This >€500 million investment will feature multiple manufacturing lines capable of supporting small, medium, and large-scale peptide production with small- to large-scale Solid Phase Peptide Synthesis (SPPS) reactors for GLP-1 and non-GLP-1 peptide projects – with a total SPPS reactor capacity of more than 5,000 L. The new state-of-the-art facility will feature advanced automation, cutting-edge digitalization, and innovative peptide production technologies, ensuring compliance with the most stringent regulations, including BLA requirements. With the main construction and qualification phase taking place between 2025 and 2027 and start of commercial activities to begin in the first half of 2028, the company is proud to generate over 300 new jobs, contributing to economic growth and innovation of the region.

In their Boulder, Colorado US facility, both expansions to existing lines and the construction of a new greenfield production area have already begun in parallel to the Switzerland initiative. The expansion will more than double the existing SPPS reactor capacity at CordenPharma Colorado by adding an additional 25,000 L of SPPS capacity – making it a total reactor capacity of >42,000 L by 2028.

Once fully operational, the Switzerland site – together with the ongoing expansions and additional greenfield capacity at CordenPharma Colorado – will significantly enhance the company’s production capabilities, solidifying CordenPharma’s position as one of the largest peptide manufacturing partners leading the CDMO peptide space.

Dr. Michael Quirmbach, President & CEO of CordenPharma Group comments: “We are excited to announce the construction of a state-of-the-art manufacturing plant just outside Basel, Switzerland, within one of the leading pharma and biotech hubs in Europe. The new facility is designed to deliver flexible and efficient peptide manufacturing to meet the growing demand of innovative peptide medicines for our customers and ultimately, patients.”

Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg comments: “CordenPharma’s bold expansion reflects its leadership in addressing the growing demand for peptide manufacturing. As a long-term investor, we are fully committed to supporting this growth, combining industrial excellence with strategic investment to strengthen CordenPharma’s position as a leading global CDMO. Ultimately, this expansion contributes to expanding access to those life-saving peptide-based medicines for patients.”

CordenPharma was acquired by Astorg, a leading Pan-European private equity firm, in 2022 to accelerate its development plans. With Astorg’s backing and these expansions, CordenPharma is well-positioned to execute its growth strategy and further strengthen its leadership in the CDMO peptide space.

About CordenPharma

CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.

With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).

The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2024 financial year, the organization generated sales of €854 million and had over 3,000 employees.

Please visit cordenpharma.com for more information I Follow CordenPharma on LinkedIn.

About Astorg

Astorg is a leading pan-European private equity firm with over €23 billion of assets under management. Astorg works with entrepreneurs and management teams to acquire market leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance and capital they need to achieve their growth goals. Enjoying a distinct entrepreneurial culture, a long-term shareholder perspective and a lean decision-making body, Astorg has valuable industry expertise in healthcare, software and technology, business services and technology-based industrial companies. Headquartered in Luxembourg, Astorg has offices in London, Paris, New York, Frankfurt, and Milan.

For more information about Astorg: www.astorg.com | Follow Astorg on LinkedIn.

CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization. With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).
CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization. With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).

Photo – https://laotiantimes.com/wp-content/uploads/2025/03/cordenpharma_aerial_sketch_of_new_peptide_greenfield_construction_near_basel_switzerland_2025_web.jpg 

Logo – https://laotiantimes.com/wp-content/uploads/2025/03/cordenpharma_logo_new.jpg